Dongxing Zha

Company: Alloy Therapeutics

Job title: Chief Executive Officer, Keyway TCR Discovery

Seminars:

Next-Generation TCRm TCE Therapeutics: A Paradigm Shift in Solid Tumor Immunotherapy 4:30 pm

TCRm targeting of undruggable intracellular proteins presents a unique opportunity for immunotherapy. T cell engagers (TCEs) are emerging as effective therapies for solid tumors. The Keyway TCRm Discovery platform provides an end-to-end workflow, delivering next-generation immunotherapies from target identification to clinical applicationRead more

day: Day 1